top of page
  • Recruiting

The PCROWD Study invites people with precursor conditions to Share samples a few times each year

Updated: Feb 10


  • The PCROWD Study invites people with precursor conditions to Share samples a few times each year when they are collected as part of routine follow up care.


  • Update 63rd ASH Annual Meeting: Non-Invasive Liquid Biopsy - Circulating Multiple Myeloma Cells


dana farber pcrowd study

78 Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease PathologyClinically Relevant Abstract

Program: Oral and Poster Abstracts

Type: Oral

Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational I

Hematology Disease Topics & Pathways:

Fundamental Science, Translational Research, Clinically Relevant

Saturday, December 11, 2021: 10:45 AM


Conclusion:

Our results demonstrate clinical correlation and molecular characterization of CMMCs from MGUS/SMM patients. This study provides a foundation for non-invasive detection, enumeration and genomic interrogation of rare CMMCs from the peripheral blood of MGUS/SMM, illustrating the clinical potential of using liquid biopsies for monitoring and managing disease in the precursor setting of MM.



 

The PCROWD Study

invites people with precursor conditions to share samples a few times each year when they are collected as part of routine follow up care. Allow us to track changes that occur in their samples and medical record

OUR STUDY'S GOAL

We aim to track 10,000 individuals with early stages of blood cancer or precursor conditions which include (in alphabetical order):

  • Clonal Hematopoiesis of Indeterminate Potential (CHIP)

  • Monoclonal B cell Lymphocytosis (MBL)

  • Myelodysplastic Syndrome (MDS)

  • Monoclonal Gammopathy of Undetermined Significance (MGUS)

  • Myeloproliferative Neoplasms (MPN) -such as Polycythemia Vera, Essential Thrombocythemia, or Myelofibrosis

  • Smoldering or Indolent Multiple Myeloma (SMM)

  • Smoldering Waldenström Macroglobulinemia (SWM)

  • OTHER precursor hematological condition

We will greatly expand the available data that will help us predict, and ultimately prevent, these types of blood cancers from progressing.

 

The IMPACT study is an affiliate study of the PROMISE and PCROWD Studies.


NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

IMPACT Study: The Immune Profiling with Antibody-based COVID-19 Testing (IMPACT) study


 

Learn more:

The Promise Study: How a Blood Test Can Detect, Intercept, and Potentially Eliminate Cancer


Dana-Farber Cancer Institute


Dana Farber Cancer Institute

Jan 31, 2022

 

Learn more:

Dr. Irene Ghobrial | CPOP | Dana-Farber Cancer Institute

Dana-Farber’s Center for the Prevention of Progression (CPOP)


Dana-Farber Cancer Institute


Learn more:

MGUS/Smoldering Myeloma PCrowd Study by Dr. Irene Ghobrial


Myeloma Crowd by HealthTree











Comments


Posts Archive
bottom of page